William Alden, MD, PhD | Medical Peptide & Fatty Acid Series
Peptide-Based Oncology Agents
By William Alden, MD, PhD | Medical Peptide, Regenerative & Fatty Acid Series
Peptides serve oncology as targeted radiotherapeutics, imaging agents, hormone-suppressing analogs, and cytotoxic natural products. Peptide receptor radionuclide therapy (PRRT) in particular has enabled a new generation of precision cancer treatment by linking a tumor-homing peptide to a therapeutic radioisotope.
Key Agents in This Class
Lutathera (Lu-177 DOTATATE).
A radiolabeled somatostatin analog that binds sst2 receptors overexpressed on neuroendocrine tumor cells and delivers beta-particle radiation from lutetium-177, producing DNA damage and cell death. FDA-approved for somatostatin-receptor-positive gastroenteropancreatic NETs.
Pluvicto (Lu-177 vipivotide tetraxetan).
A PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. The peptide component binds prostate-specific membrane antigen; lutetium-177 delivers localized radiation.
Octreotide and lanreotide.
Somatostatin analogs that control hormone secretion in functional neuroendocrine tumors and exert antiproliferative effects via sst2-mediated signaling. FDA-approved.
Romidepsin, bleomycin, dactinomycin.
Peptide or depsipeptide natural products used as cytotoxic agents. Romidepsin is an HDAC inhibitor for certain T-cell lymphomas; bleomycin generates DNA strand breaks; dactinomycin intercalates DNA and blocks transcription.
Pegulicianine and plitidepsin.
Pegulicianine is a fluorescent peptide imaging probe used intraoperatively to identify tumor margins. Plitidepsin is a marine depsipeptide approved abroad for multiple myeloma.
Evidence and Regulatory Status
This is a strongly FDA-approved domain, anchored by the peptide-targeted radiotherapeutics that pair a high-affinity tumor-seeking peptide with a therapeutic isotope. The same receptor targets are often exploited first for diagnostic PET imaging (test-and-treat pairing). Cytotoxic peptide natural products remain important in selected regimens.
Frequently Asked Questions
What is a test-and-treat pairing?
An imaging tracer identifies tumors that express a given target; a matching therapeutic radioligand then delivers treatment to those same targets.
Why use peptide PET tracers?
A receptor-targeting peptide can localize disease with high specificity, guiding both diagnosis and subsequent therapy selection while minimizing non-specific background.
How does the cosyntropin test work?
Synthetic ACTH(1-24) is administered and serial cortisol levels are measured. An inadequate rise indicates primary or secondary adrenal insufficiency.
Clinical Perspective
Peptide targeting has quietly become one of the most elegant ideas in oncology—turning a homing peptide into a precision delivery vehicle for radiation or, in other cases, for imaging or cytotoxicity.
Read more about this: [Reproductive Health: GnRH Agents and Fertility Peptides] and [Obstetric and Oxytocin Peptides].
About the Author
William “Wes” Alden, MD, PhD, is a physician-scientist and internist whose career spans academic medicine, federal clinical research, community healthcare, and medical philanthropy. His work sits at the intersection of laboratory science and bedside care, and his writing consistently returns to one theme: regenerative and metabolic therapies deserve both open-minded use and rigorous scientific and regulatory scrutiny. This series surveys the major categories of therapeutic peptides and healthful fatty acids, one blog at a time, with an emphasis on honest evidence and clear regulatory status.
Important Disclosure and Disclaimer
This content is for general education and reflects Dr. Alden’s professional perspective. It is not medical advice and does not create a doctor-patient relationship. Individual results vary, and many agents discussed are not FDA-approved for the uses described. Several peptides are not FDA-approved and have an evolving federal compounding status; products labeled for research use only are never appropriate for use in people. Most fatty acids discussed are foods or dietary supplements and are not FDA-approved to treat any condition. Any peptide or compounded agent should be used only through a licensed provider, with appropriately sourced pharmaceutical-grade material. Readers should consult a qualified healthcare professional about their own situation before pursuing any treatment.
Educational content reflecting Dr. Alden’s professional perspective. Not medical advice. Several agents named are not FDA-approved and some have an evolving compounding status. See the full disclosure accompanying this series.

November 18, 2026
4 min read




Back to Blog